An Open-label, Phase Ib Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Select Subjects With Lymphoma or Chronic Lymphocytic Leukemia
Phase of Trial: Phase I
Latest Information Update: 14 Jul 2016
At a glance
- Drugs Duvelisib (Primary) ; Bendamustine; Rituximab
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; T-cell lymphoma
- Focus Adverse reactions
- 07 Jul 2016 Status changed from active, no longer recruiting to completed.
- 24 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 Jul 2016.
- 15 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.